Antonio Sergio Navarro Fernandez
Direktor/Vorstandsmitglied bei Universal Diagnostics SA
Aktive Positionen von Antonio Sergio Navarro Fernandez
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Universal Diagnostics SA
Universal Diagnostics SA Electronic Equipment/InstrumentsElectronic Technology Universal Diagnostics SL is a bioinformatics and multi-omics company based in Seville, Spain. The Spanish company's mission is to transform cancer into a curable disease by developing blood tests that detect cancer in its earliest stages. The company's first single-draw blood test, Signal-C, accurately detects colorectal cancer with a sensitivity rate of 92%% and specificity rate of 97%%, with extraordinary accuracy for earlier stages (89%%/97%%). The company is developing Signal-X™, a multi-cancer platform able to detect various types of high-burden cancers with high sensitivity and tissue-of-origin specificity. With its multi-omics + computational biology + machine learning approach, the company is cracking the code to "true" early cancer detection, having identified the specific cfdna sequence regions that capture cancer's earliest signal with +90%% accuracy. The company was founded by Marko Bitenc and Juan Martínez Barea, with Juan Martínez Barea serving as the CEO since incorporation. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Antonio Sergio Navarro Fernandez
Statistik
International
Spanien | 2 |
Operativ
Director/Board Member | 1 |
Sektoral
Electronic Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Universal Diagnostics SA
Universal Diagnostics SA Electronic Equipment/InstrumentsElectronic Technology Universal Diagnostics SL is a bioinformatics and multi-omics company based in Seville, Spain. The Spanish company's mission is to transform cancer into a curable disease by developing blood tests that detect cancer in its earliest stages. The company's first single-draw blood test, Signal-C, accurately detects colorectal cancer with a sensitivity rate of 92%% and specificity rate of 97%%, with extraordinary accuracy for earlier stages (89%%/97%%). The company is developing Signal-X™, a multi-cancer platform able to detect various types of high-burden cancers with high sensitivity and tissue-of-origin specificity. With its multi-omics + computational biology + machine learning approach, the company is cracking the code to "true" early cancer detection, having identified the specific cfdna sequence regions that capture cancer's earliest signal with +90%% accuracy. The company was founded by Marko Bitenc and Juan Martínez Barea, with Juan Martínez Barea serving as the CEO since incorporation. | Electronic Technology |